

## Drug Utilization Review Board Meeting

**December 10 , 2013**

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>New Drug Reviews</b>			
<b>Antineoplastics</b>			
	Cometriq (Oral) Capsule	P/PA	P/PA
	Pomalyst (Oral) Capsule	P/PA	P/PA
<b>Ophthalmic Miscellaneous</b>			
	Cystaran (Ophthalmic) Drops	P	P
<b>Antiemetic</b>			
	Diclegis (Oral) Tablet Delayed- Release	NP	NP
<b>Antidiarrheal</b>			
	Fulyzaq (Oral) Tablet Delayed- Release	NP/PA	NP/PA
<b>Antidiabetics</b>			
	Invokana (Oral) Tablet	NP/PA	NP/PA
	Nesina (Oral) Tablet	NP/PA	NP/PA
<b>Ophthalmic Prostaglandin</b>			
	Rescula (Ophthalmic) Drops	NP/PA	NP/PA
<b>Somatostatic Agent</b>			
	Signifor (Subcutaneous) Ampule	NP/PA	NP/PA
<b>Antimycobacterial Agent</b>			
	Sirturo (Oral) Tablet	P/PA	P/PA
<b>Multiple Sclerosis Agent</b>			
	Tecfidera (Oral) Capsule Delayed- Release	NP/PA	NP/PA
<b>Ganglionic Blocker</b>			
	Vecamyl (Oral) Tablet	NP/PA	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization